Bladder Cancer

March 17, 2021

Adjuvant nivolumab is the first immunotherapy to demonstrate a benefit in the treatment of high-risk muscle-invasive urothelial carcinoma

Some patients are not eligible for cisplatin due to factors such as reduced kidney function. Adjuvant nivolumab, in turn, may represent a treatment option for these individuals, in […]
Do you like it?
Read more
March 17, 2021

Enfortumab vedotin shows long-lasting responses to advanced urothelial cancer in cisplatin-ineligible patients who received anti-PD-(L)1

Enfortumab vedotin (EV) is an antibody-drug conjugate, that is directed against Nectin-4, an immunoglobulin-like cell adhesion molecules, highly expressed in urothelial carcinoma EV-201 (NCT03219333) is a […]
Do you like it?
Read more
March 17, 2021

N-803, a superagonist of IL-15RαFc, shows promising efficacy in the treatment of bladder carcinoma in situ   

Patients with non-muscle–invasive urothelial carcinoma of the bladder who do not respond to BCG have limited treatment options. N-803 is an immunostimulant protein fusion complex based on mutant IL-15 (IL-15RαFc), […]
Do you like it?
Read more
March 16, 2021

DUART trial assesses the association of radiotherapy and durvalumab for the treatment of localized urothelial cancer of the bladder

Patients with locally advanced or unresectable bladder cancer, ineligible for cisplatin or not candidates for surgery, have limited treatment options. Immunotherapy associated with radiotherapy has been analyzed in […]
Do you like it?
Read more
April 29, 2019

FDA approves first targeted therapy for locally advanced or metastatic bladder cancer

Balversa (erdafitinib) is one of the first fibroblast growth factor receptor (FGFR) kinase inhibitors to be approved for the treatment of locally advanced or metastatic bladder […]
Do you like it?
Read more